Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 1/20 | 0.44 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.43 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL397191 | 0.84 | GSK3B (0.50) | GSK3BKCNH2MCL1 | |
| SCHEMBL11338354 | 0.83 | FOLH1 (0.41) | GSK3BCTSBFOLH1 | |
| SCHEMBL3033628 | 0.80 | BCL2 (0.50) | BCL2KAT6ASMYD3CNR2LOXL2 | |
| SCHEMBL30951011 | 0.79 | PARP1 (0.52) | GSK3BKCNH2 | |
| SCHEMBL135970 | 0.79 | PARP1 (0.52) | GSK3BKCNH2 | |
| SCHEMBL1786567 | 0.79 | PARP1 (0.52) | GSK3BCTSBKCNH2 | |
| SCHEMBL135211 | 0.79 | ALDH1A1 (0.53) | — | |
| SCHEMBL924897 | 0.79 | CYP4F2 (0.49) | BCL2KAT6ASMYD3CNR2LOXL2 | |
| Acetonitrile SCHEMBL17008407 | 0.79 | PARP1 (0.47) | GSK3BCTSBKCNH2 | |
| SCHEMBL7827586 | 0.79 | LOXL2 (0.51) | LOXL2CYP4F2CYP4A11MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11578071-B2 | Preparation of pyrazolo[3,4-B]pyridines as antimalarials | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2023-02-14 | — | — | US | disclosed |
| US-20210101901-A1 | PREPARATION OF PYRAZOLO[3,4-B]PYRIDINES AS ANTIMALARIALS | CAL POLY CORPORATION | 2021-04-08 | — | — | US | disclosed |
| WO-2021067967-A1 | PREPARATION OF PYRAZOLO[3,4-B]PYRIDINES AS ANTIMALARIALS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2021-04-08 | — | — | WO | disclosed |
| EP-1928455-A1 | ANILINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | Bayer Healthcare, LLC (US) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007027842-A1 | ANILINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | BAYER HEALTHCARE LLC (US) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007027842-A1 | ANILINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | BAYER HEALTHCARE LLC (US) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210101901-A1 | PREPARATION OF PYRAZOLO[3,4-B]PYRIDINES AS ANTIMALARIALS | PNPO, NOX3, G6PD | BCL2 1497/4885KAT6A 3844/4885SMYD3 1795/4885 |
| US-11578071-B2 | Preparation of pyrazolo[3,4-B]pyridines as antimalarials | PNPO, NOX3, G6PD | BCL2 1497/4885KAT6A 3844/4885SMYD3 1795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.